These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 31978044)

  • 21. Cost-effectiveness analysis of dabigatran versus rivaroxaban for stroke prevention in patients with non-valvular atrial fibrillation using real-world evidence in elderly US Medicare beneficiaries.
    Peng S; Deger KA; Ustyugova A; Gandhi P; Qiao N; Wang C; Kansal AR
    Curr Med Res Opin; 2018 Jan; 34(1):55-63. PubMed ID: 28862479
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical and economic impact of rivaroxaban on the burden of atrial fibrillation: The case study of Japan.
    Hori M; Ikeda S; Okumura K; Matsuda S; Koretsune Y; Montouchet C; Watanabe-Fujinuma E; Evers T; Rossi B; Ruff L; Briere JB
    J Med Econ; 2016 Sep; 19(9):889-99. PubMed ID: 27112188
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of rivaroxaban versus warfarin for treatment of nonvalvular atrial fibrillation in patients with worsening renal function.
    Salcedo J; Hay JW; Lam J
    Int J Cardiol; 2019 May; 282():53-58. PubMed ID: 30518479
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
    Lanitis T; Cotté FE; Gaudin AF; Kachaner I; Kongnakorn T; Durand-Zaleski I
    J Med Econ; 2014 Aug; 17(8):587-98. PubMed ID: 24831811
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patient-reported treatment satisfaction and budget impact with rivaroxaban vs. standard therapy in elective cardioversion of atrial fibrillation: a post hoc analysis of the X-VeRT trial.
    Hohnloser SH; Cappato R; Ezekowitz MD; Evers T; Sahin K; Kirchhof P; Meng IL; van Eickels M; Camm AJ;
    Europace; 2016 Feb; 18(2):184-90. PubMed ID: 26487668
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
    Lip GY; Kongnakorn T; Phatak H; Kuznik A; Lanitis T; Liu LZ; Iloeje U; Hernandez L; Dorian P
    Clin Ther; 2014 Feb; 36(2):192-210.e20. PubMed ID: 24508420
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Health economic evaluation of rivaroxaban in elective cardioversion of atrial fibrillation.
    Jacobs MS; de Jong LA; Postma MJ; Tieleman RG; van Hulst M
    Eur J Health Econ; 2018 Sep; 19(7):957-965. PubMed ID: 29181817
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness.
    Kansal AR; Sharma M; Bradley-Kennedy C; Clemens A; Monz BU; Peng S; Roskell N; Sorensen SV
    Thromb Haemost; 2012 Oct; 108(4):672-82. PubMed ID: 22898892
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
    Freeman JV; Zhu RP; Owens DK; Garber AM; Hutton DW; Go AS; Wang PJ; Turakhia MP
    Ann Intern Med; 2011 Jan; 154(1):1-11. PubMed ID: 21041570
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Economic evaluation of the use of non-vitamin K oral anticoagulants in patients with atrial fibrillation on antiplatelet therapy: a modelling analysis using the healthcare system in the Netherlands.
    Bennaghmouch N; de Veer AJWM; Mahmoodi BK; Jofre-Bonet M; Lip GYH; Bode K; Ten Berg JM
    Eur Heart J Qual Care Clin Outcomes; 2019 Apr; 5(2):127-135. PubMed ID: 30016398
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-Effectiveness of Left Atrial Appendage Closure With the WATCHMAN Device Compared With Warfarin or Non-Vitamin K Antagonist Oral Anticoagulants for Secondary Prevention in Nonvalvular Atrial Fibrillation.
    Reddy VY; Akehurst RL; Amorosi SL; Gavaghan MB; Hertz DS; Holmes DR
    Stroke; 2018 Jun; 49(6):1464-1470. PubMed ID: 29739915
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of different strategies for stroke prevention in patients with atrial fibrillation in a health resource-limited setting.
    Wu B; Kun L; Liu X; He B
    Cardiovasc Drugs Ther; 2014 Feb; 28(1):87-98. PubMed ID: 24048510
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of rivaroxaban versus warfarin in non-valvular atrial fibrillation patients with chronic kidney disease in China.
    Liu L; Hong D; Ma K; Lu X
    J Clin Pharm Ther; 2021 Jun; 46(3):658-668. PubMed ID: 33226144
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of dabigatran etexilate in the prevention of stroke and systemic embolism in patients with atrial fibrillation in Belgium.
    Wouters H; Thijs V; Annemans L
    J Med Econ; 2013; 16(3):407-14. PubMed ID: 23320796
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation in the Japanese healthcare setting.
    Hori M; Tanahashi N; Akiyama S; Kiyabu G; Dorey J; Goto R
    J Med Econ; 2020 Mar; 23(3):252-261. PubMed ID: 31687870
    [No Abstract]   [Full Text] [Related]  

  • 36. Effectiveness and Safety of Rivaroxaban 15 or 20 mg Versus Vitamin K Antagonists in Nonvalvular Atrial Fibrillation.
    Blin P; Fauchier L; Dureau-Pournin C; Sacher F; Dallongeville J; Bernard MA; Lassalle R; Droz-Perroteau C; Moore N
    Stroke; 2019 Sep; 50(9):2469-2476. PubMed ID: 31390972
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases.
    Maura G; Billionnet C; Alla F; Gagne JJ; Pariente A
    Pharmacotherapy; 2018 Jan; 38(1):6-18. PubMed ID: 29028119
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Number needed to treat based on real-world evidence for non-vitamin K antagonist oral anticoagulants versus vitamin K antagonist oral anticoagulants in stroke prevention in patients with non-valvular atrial fibrillation.
    Briere JB; Bowrin K; Millier A; Toumi M; Wojciechowski P; Taieb V
    J Med Econ; 2019 Aug; 22(8):760-765. PubMed ID: 30969801
    [No Abstract]   [Full Text] [Related]  

  • 39. Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for atrial fibrillation in Portugal.
    Costa J; Fiorentino F; Caldeira D; Inês M; Lopes Pereira C; Pinheiro L; Vaz-Carneiro A; Borges M; Gouveia M
    Rev Port Cardiol; 2015 Dec; 34(12):723-37. PubMed ID: 26616542
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-world cost-effectiveness of rivaroxaban and apixaban vs VKA in stroke prevention in non-valvular atrial fibrillation in the UK.
    Bowrin K; Briere JB; Levy P; Millier A; Tardu J; Toumi M
    J Mark Access Health Policy; 2020 Jun; 8(1):1782164. PubMed ID: 32944199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.